Moxonidine

• Description :

  Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis[1][2][3][4][5][6][7].

• Product Name Alternative :

  BDF5895

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H411

• Target :

  Adrenergic Receptor; Imidazoline Receptor; LDLR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/moxonidine.html

• Concentration :

  10mM

• Purity :

  99.72

• Solubility :

  DMSO : 20 mg/mL (ultrasonic)

• Smiles :

  CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1

• Molecular Formula :

  C9H12ClN5O

• Molecular Weight :

  241.68

• Precautions :

  H301, H411

• References & Citations :

  [1]Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82.|[2]Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24 (4) :3857.|[3]Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409 (4) :645-50. |[4]Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126 (6) :1522-30.|[5]Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397 (1) :113-20.|[6]Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362 (1) :61-7.|[7]Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603 (1-3) :73-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [75438-57-2]